CTOs on the Move

Barry`s

www.barrys.com

 
Barry`s game-changing fitness classes offer our global community, the OG #FitFam, the Best Workout in the World® -- a workout that is as effective as it is fun. Founded in 1998, Barry`s has led the fitness industry in innovation. Today, you can experience our signature Red Room in more than 70 studios across 10 countries, as well as in the comfort of your own home. Whether you`re sprinting, lifting, or riding, in-studio or at-home, we`re on a mission to inspire you to work(out) hard, have fun, find your strength, and be your best.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.barrys.com
  • 7373 Beverly Blvd
    Los Angeles, CA USA 90036
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Medaudit Services Inc

Medaudit Services Inc is a Midland, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ChemoMetec

ChemoMetec is a worldwide leading manufacturer of automated cell counters and analysis equipment. We work closely with life science companies, research institutes, universities, hospitals, specialist clinics, and a wide range of food and beverage manuf...

CareQuest Inc

CareQuest Inc is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PinpointCare

Care delivery has become dysfunctional. Its fragmented, impersonal, and expensive — but it doesnt have to be. PinpointCare is a cloud-based, flexible SaaS solution that gives healthcare professionals the power to coordinate care across the entire continuum without disrupting their workflow. Patients are engaged in creating personalized care plans and information is shared across sites of care, enabling healthcare providers to make informed decisions to better manage risk, reduce costs and improve quality.

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.